News Releases | CSL

Month Year

Month Year

May 24, 2016

Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 24, 2016

Vifor Pharma to further strengthen company management to ensure continued strong growth.

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 23, 2016

The 2016 ESC heart failure guidelines strongly recommend Ferinject® for the treatment of iron deficiency in patients with systolic heart failure

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 11, 2016

Change to the shareholder structure of the Galenica Group

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 10, 2016

Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s OrallyAdministered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 10, 2016

Vifor Pharma appoints Colin Bond as Chief Financial Officer

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 9, 2016

Vifor Fresenius Medical Care Renal Pharma and OPKO Health enter into Agreement for OPKO’s RAYALDEE

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Apr 28, 2016

88th Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Apr 25, 2016

Vifor Fresenius Medical Care Renal Pharma submits marketing authorisation application requesting European approval of Patiromer for treatment of hyperkalemia

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Mar 15, 2016

Galenica 2015: profit increased for the 20th consecutive year

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases

Show per page

Filter by Company: